Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

By F. Feres, R. Costa, A. Abizaid, M. Leon, J. Marin-Neto, R. Botelho, S. King, M. Negoita, Minglei Liu, J. E. T. de Paula and 14 more. Journal of the American Medical Association (JAMA), 2013

670 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/090957e5a798b19f100ba9d3e8d20defb5f26b4b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. O'Gara
2. Jose Luis Zamorano
3. M. Mack
4. L. Fleisher
5. Stephan Windecker

Citations in the corpus

• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “IIb C-LD In patients with SIHD treated with DA with oral anticoagulant therapy), are or develop significant overt bleeding, (19,20,34,36,37).”
• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, methodology): “71 ABBREVIATIONS AND ACRONYMS ABC Age, Biomarkers (GDF-15, cTnT-hs, and haemoglobin), and Clinical history (previous bleeding) ACCA Acute Cardiovascular Care Association ACCOAST A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention Or as Pretreatment At the Time of Diagnosis in”